Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) insider Linda Llewelyn sold 1,324 shares of the firm's stock in a transaction on Monday, September 16th. The stock was sold at an average price of $8.43, for a total transaction of $11,161.32. Following the completion of the sale, the insider now owns 115,599 shares of the company's stock, valued at approximately $974,499.57. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Linda Llewelyn also recently made the following trade(s):
- On Thursday, August 15th, Linda Llewelyn sold 1,328 shares of Health Catalyst stock. The stock was sold at an average price of $6.57, for a total transaction of $8,724.96.
- On Monday, July 15th, Linda Llewelyn sold 1,290 shares of Health Catalyst stock. The shares were sold at an average price of $6.51, for a total value of $8,397.90.
Health Catalyst Price Performance
Shares of HCAT opened at $8.74 on Thursday. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The stock has a market cap of $515.97 million, a price-to-earnings ratio of -4.72 and a beta of 1.31. The firm has a 50 day simple moving average of $7.20 and a 200-day simple moving average of $6.90.
Trump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absolute
From Monetary Gold | Ad
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs).
If these plans are implemented, it could mean the end of America as we know it.
This means you must act NOW before it's too late.
Health Catalyst (NASDAQ:HCAT - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The company had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. During the same quarter last year, the business posted ($0.21) earnings per share. Health Catalyst's revenue was up 3.7% compared to the same quarter last year. On average, equities analysts expect that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in HCAT. Nisa Investment Advisors LLC boosted its stake in shares of Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company's stock worth $41,000 after purchasing an additional 5,232 shares during the last quarter. Quarry LP boosted its position in Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company's stock worth $45,000 after acquiring an additional 2,610 shares during the last quarter. Perfromance Wealth Partners LLC purchased a new stake in Health Catalyst in the 2nd quarter worth approximately $64,000. Mackenzie Financial Corp purchased a new stake in Health Catalyst in the 2nd quarter worth approximately $70,000. Finally, EntryPoint Capital LLC acquired a new position in Health Catalyst in the 1st quarter valued at $98,000. Institutional investors and hedge funds own 85.00% of the company's stock.
Analysts Set New Price Targets
Several analysts have recently commented on HCAT shares. Piper Sandler reduced their price target on Health Catalyst from $14.00 to $11.00 and set an "overweight" rating for the company in a report on Monday, August 26th. Stephens reduced their target price on Health Catalyst from $8.00 to $7.00 and set an "equal weight" rating for the company in a report on Thursday, August 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $16.00 price target on shares of Health Catalyst in a research note on Tuesday, August 20th. JPMorgan Chase & Co. raised their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Wednesday, September 4th. Finally, Evercore ISI lowered their target price on shares of Health Catalyst from $9.00 to $8.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 9th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $11.42.
Get Our Latest Stock Analysis on HCAT
About Health Catalyst
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
